Electrophysiology

CathVision CEO Mads Matthiesen to Present at LSI Europe

Retrieved on: 
Wednesday, September 20, 2023
Electrophysiology, LSI, Sales

COPENHAGEN, Denmark, Sept. 20, 2023 /PRNewswire/ -- Mads Matthiesen, CEO of CathVision, is scheduled to speak on September 21 at the prestigious LSI Europe Emerging Medtech Summit partnering event that brings together global innovators, investors, and strategics working to advance healthcare.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 20, 2023 /PRNewswire/ -- Mads Matthiesen, CEO of CathVision, is scheduled to speak on September 21 at the prestigious LSI Europe Emerging Medtech Summit partnering event that brings together global innovators, investors, and strategics working to advance healthcare.
  • Mr. Matthiesen's presentation will include an overview of CathVision's innovative electrophysiology solutions, including the ECGenius System and CARDIALYTICS suite of artificial intelligence-powered analytics; highlights of clinical and regulatory milestones; details of the market opportunity and the ability to accelerate commercial adoption; and potential investment opportunities.1
    Investors and strategic partners attending the event can schedule meetings with Mr. Matthiesen through the LSI platform or by emailing [email protected] .
  • The entire presentation will be available following the conference for those interested.
  • Please contact CathVision to request the presentation.

Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research

Retrieved on: 
Monday, September 18, 2023
Health, Stem Cells, Other Health, Research, Science, Pharmaceutical, Biotechnology, SBS, Tissue, Bio, Culture, 3D, Multimedia, Cell, 2D, Data analysis, Myogenesis, Acquisition, Curi, Organoid, Electrophysiology, Patient safety, Drug discovery, Ecosystem, Safety, Medical imaging, Nautilus, Stingray, Pulse

Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery.

Key Points: 
  • Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery.
  • View the full release here: https://www.businesswire.com/news/home/20230918918911/en/
    Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research (Photo: Business Wire)
    The Nautilus and Stingray platforms are both available as standalone bioscience instruments.
  • Curi Bio’s mission of democratizing these once inaccessible approaches continues with the commercial launch of Nautilus and Stingray.
  • “At Curi Bio, our goal is to provide researchers with innovative, turnkey solutions to accelerate the discovery of new medicines,” said Dr. Nicholas Geisse, CEO of Curi Bio.

JenaValve Appoints Shlomi Nachman to Board of Directors

Retrieved on: 
Thursday, September 14, 2023
Aortic stenosis, Technion – Israel Institute of Technology, Johnson & Johnson, Research, Economics, J&J, Chemistry, Optometry, Patient, TAVR, Ear, Arnold, AR, Electricity, Electrophysiology, Nursing, Science, Cordis, Ophthalmology

IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.
  • “We are thrilled to welcome Shlomi to the JenaValve Board of Directors,” said John Kilcoyne, Chief Executive Officer.
  • “His experience as both an executive and board member across innovative cardiovascular device businesses further strengthens the operating expertise of our board.
  • Mr. Nachman stated, “I am grateful to have the opportunity to join JenaValve at such an exciting time in the company’s development.

Attune Medical’s ensoETM™ Granted FDA De Novo Marketing Authorization to Reduce the Likelihood of Ablation-related Esophageal Injury Resulting from Radiofrequency Cardiac Ablation Procedures

Retrieved on: 
Thursday, September 14, 2023
Science, Cardiology, Biotechnology, Research, Health, FDA, Clinical Trials, Other Health, Medicine, US Foods, FHRS, De novo, Atrial fibrillation, Esophagus, Multimedia, Temperature, AEF, NorthShore University HealthSystem, Cardiac electrophysiology, Operating, Hospital, Journal, Patient, Physician, Risk, Electrophysiology, IMPACT, Fluoroscopy, American College, Safety, Medical device, Pharmaceutical industry, MD

Attune Medical has been granted De Novo marketing authorization from the US Food and Drug Administration (FDA) for its ensoETM device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.

Key Points: 
  • Attune Medical has been granted De Novo marketing authorization from the US Food and Drug Administration (FDA) for its ensoETM device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.
  • View the full release here: https://www.businesswire.com/news/home/20230914650329/en/
    Attune Medical has been granted De Novo marketing authorization from the US Food and Drug Administration (FDA) for its ensoETM device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.
  • It is the most common type of cardiac ablation procedure, with over 300,000 per year performed in the US alone.
  • This De Novo marketing authorization expands the ensoETM’s indications for use to reduce the likelihood of esophageal injury resulting from radiofrequency cardiac ablation procedures.

New Study Describes First, Functional Human Model to Investigate Opiate Overdose and Recovery

Retrieved on: 
Thursday, September 7, 2023
University, Biotechnology, Education, Technology, Health, Pharmaceutical, Other Science, Other Technology, Research, Nanotechnology, Science, Molecular biology, Central Florida, Spanish National Center for Biotechnology, Heart, Neuron, Human, Cell biology, Therapy, Opioid, Naloxone, UCF, Systems biology, Public, Initiative, NCATS, Fentanyl, Toxicity, National Center for Advancing Translational Sciences, Bangladesh Technical Education Board, Skeletal muscle, Bio-MEMS, Chemistry, Development, Student, Patient, Electrophysiology, Engineering, Kidney, Drug discovery, Faculty, Drug, Liver, NSTC, HSL, Death, NIH, Medical imaging, Pharmaceutical industry

The study, "Human IPSC-Derived PreBötC-like Neurons and Development of an Opiate Overdose and Recovery Model" ( doi.org/10.1002/adbi.202300276 ) was published in Advanced Biology on September 7, 2023.

Key Points: 
  • The study, "Human IPSC-Derived PreBötC-like Neurons and Development of an Opiate Overdose and Recovery Model" ( doi.org/10.1002/adbi.202300276 ) was published in Advanced Biology on September 7, 2023.
  • The paper describes the development of human preBötC neurons from induced pluripotent cells (iPSCs) and the establishment of a human model that mimics opioid overdose with four opioids and the recovery of neuronal activity with naloxone treatment.
  • The dose-dependent inhibition of these neurons’ activity was demonstrated with four opioids, including Fentanyl - the primary culprit of overdose deaths.
  • “This research provides an accurate way to model overdose in the lab, using human brain cells programmed to respond to many different opioids,” said Rebecca Baker.

Akron Children's, GlobalCastMD to host conference on cardioneuroablation

Retrieved on: 
Monday, September 11, 2023
Akron Children's Hospital, Learning, Heart, Seizure, Radiation, Sinus node dysfunction, Emergency medicine, Cardiac catheterization, Vagus nerve, Atrial fibrillation, PDT, DRS, Second, Cardiology, Neurology, CNA, EDT, Heart block, Management of atrial fibrillation, Patient, Physician, Electrophysiology, Fluoroscopy, Hospital, Reflex syncope, Heart rate, Pediatrics, Paulo, Medical device

AKRON, Ohio, Sept. 11, 2023 /PRNewswire/ -- Akron Children's Hospital and GlobalCastMD will co-host the Second World Congress on Cardioneuroablation, a live, virtual conference, on Oct. 21 from 11 a.m. EDT, 8 a.m. PDT.

Key Points: 
  • AKRON, Ohio, Sept. 11, 2023 /PRNewswire/ -- Akron Children's Hospital and GlobalCastMD will co-host the Second World Congress on Cardioneuroablation, a live, virtual conference, on Oct. 21 from 11 a.m. EDT, 8 a.m. PDT.
  • Dr. Pachón is director of the São Paulo Heart Hospital Arrhythmia Service in São Paulo, Brazil.
  • Dr. Clark is director of electrophysiology at Akron Children's Hospital in Akron, Ohio.
  • This conference is suggested for not only electrophysiologists and cardiologists, but also neurologists, general medicine practitioners, emergency medicine physicians, pediatricians, and allied health professionals.

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

Retrieved on: 
Wednesday, September 6, 2023
Neuromuscular disease, PGN, Heart, Human, Myotonic Dystrophy Foundation, Duchenne muscular dystrophy, Therapy, NMD, DM1, Safety, Peptide, Cell, RNA, Duchenne, Myotonic dystrophy, Myotonia, EDO, DMD, Electrophysiology, NHP, Conference, MDF, Oligonucleotide, Potential, Disease, Pharmaceutical industry, Fine chemical, Tolerability, Pharmacokinetics, Biology

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023 in Ottawa, ON, Canada, and at the 2023 Myotonic Dystrophy Foundation (MDF) Annual Conference being held on September 7-9, 2023 in Washington, D.C.

Key Points: 
  • Additionally, the presentation reported that EDO technology was also shown to improve in vivo nuclear delivery, with 72% of skeletal muscle nuclei in NHPs positive for oligonucleotide following two doses at 30mg/kg.
  • PepGen previously demonstrated that a single dose of 30 mg/kg of PGN-EDODM1 corrected myotonia in the DM1 HSALR mouse model as measured by electrophysiology.
  • Treatment emergent adverse events in this study at these dose levels were transient, mild (grade 1), and reversible and did not require intervention.
  • “We have previously demonstrated the ability of the EDO technology to deliver up to 50 nM of oligonucleotide to biceps in humans following a single dose.

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

Retrieved on: 
Wednesday, September 6, 2023
Partnership, Copenhagen University Hospital, Heart failure, Arrest, Stroke, Genesis, Arrhythmia, Robotic magnetic navigation, Hospital, Patient, Physician, Risk, Rigshospitalet, Health, NYSE, Shahid Gangalal National Heart Centre, Safety, Electrophysiology, Medical device, Nursing, Stereotaxis

The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders.

Key Points: 
  • The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders.
  • Electrophysiologists at The Heart Centre Rigshospitalet were early pioneers, and are global leaders, in the use of advanced robot technology for the treatment of cardiac arrhythmias.
  • Since installation of the first robotic system in 2006, Rigshospitalet physicians have successfully treated over 5,000 patients using Stereotaxis’ robotic technology.
  • “We look forward to continuing a strong collaboration that advances patient care, clinical science, and technology development in electrophysiology.”

Vektor Medical Unveils Enhanced vMap Technology for Accurate, Non-invasive Mapping of Cardiac Arrhythmias

Retrieved on: 
Wednesday, September 6, 2023
Radiology, Health Technology, Health, Cardiology, Heart, Uncertainty, Medicine, Extended play, Noise, Vector, UC San Diego Health, ECG, Multimedia, Automation, Physician, EP, Arrhythmia, FDA, Medical device, Medical imaging, Electrophysiology

Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ECG data, today announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap.

Key Points: 
  • Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ECG data, today announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap.
  • Designed to improve ablation outcomes and procedural efficiencies, the newly updated vMap software integrates additional automation and advanced visualization features.
  • View the full release here: https://www.businesswire.com/news/home/20230906303835/en/
    With advanced visualization and automation features, vMap empowers physicians to accurately identify the source location of cardiac arrhythmias.
  • These updates highlight Vektor Medical’s commitment to continuous innovation to transform arrhythmia care.

Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment

Retrieved on: 
Wednesday, August 30, 2023
Heart, Heart failure, Arrest, Atrial fibrillation, Stroke, Hope, Electrophysiology, Arrhythmia, BSN, RMN, Robotic magnetic navigation, Ventricular tachycardia, Patient, Physician, Risk, EP, RN, Health, Overland Park Regional Medical Center, RCIS, NYSE, Genesis, Safety, Medical device, MD

OPRMC – part of HCA Midwest Health, Kansas City’s largest healthcare provider – is the only hospital in the U.S. to offer two Stereotaxis Robotic Magnetic Navigation systems for patients receiving minimally invasive cardiac ablation procedures.

Key Points: 
  • OPRMC – part of HCA Midwest Health, Kansas City’s largest healthcare provider – is the only hospital in the U.S. to offer two Stereotaxis Robotic Magnetic Navigation systems for patients receiving minimally invasive cardiac ablation procedures.
  • “Establishing a second robotic electrophysiology lab allows for additional capacity and opportunities to provide the high-quality, compassionate patient care we are known for to the communities we serve,” says Overland Park Regional Medical Center CEO Matt Sogard.
  • “I’ve worked with Dr. Lakkireddy in the EP lab at Overland Park Regional Medical Center since 2018 and had complete confidence in him,” said Mr. Kellogg.
  • “The initial procedures with Genesis went very well,” said Dhanunjaya “DJ” Lakkireddy, MD, Electrophysiologist and Executive Medical Director of Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center.